Here are three things to know:
1. Following U.S., European Union, Russian and South Korean approval, Cellect’s patent has now been approved in Japan and Australia.
2. The patent covers devices using Cellect’s Apograft technology, which is designed to replace costly and complex stem cell isolation methods.
3. The patent covers container devices comprised of a biocompatible material and a biologically active cell surface. Apograft-using devices are intended for bone marrow transplants, diabetes, inflammatory bowel disease, graft-versus-host-disease and more.
More articles on biologics:
OsteoRemedies unveils 1st FDA-cleared dual-antibiotic spacer & bone cement: 3 notes
MTF Biologics & Academy Medical join forces to bring allografts to the VA: 4 notes
ORTHOReBIRTH USA & neurosurgeon partner to develop biologic solutions: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.